Media Center

News Releases

Kythera Biopharmaceuticals Receives Notice of Allowance for Additional U.S. Patent on ATX-101 (Formulations Of Deoxycholic Acid and Salts)
December 14, 2011

New formulation patent expands intellectual property protection for ATX-101, a first-in-class, injectable drug under clinical investigation for the reduction of fat under the chin. LOS ANGELES, December 14, 2011 (Business Wire) – KYTHERA Biopharmaceuticals, Inc. (KYTHERA), a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, announced today that…

Kythera Biopharmaceuticals Presents Long-Term Follow-Up Study Results From Phase 2 Trials With ATX-101
November 7, 2011

Long-Term Study Results Through 2 Years Demonstrate Sustained Aesthetic Correction by Patient and Physician Evaluation and Long-Term Tolerability of ATX-101 LOS ANGELES, November 7, 2011 (Business Wire) – KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”), a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, presented results from a long-term follow up…

KYTHERA Biopharmaceuticals Announces Preliminary Two-Year Follow-Up Study Results and Poster Presentation of Phase 2B Data from Investigational Fat Reduction Drug at ASDS
November 2, 2011

What: Oral Presentation of Preliminary Two-Year Long-Term Follow-Up Study Results from Phase 2 Trials with ATX-101 for the Reduction of Localized Fat. Poster Presentation of Results from a Phase 2B Study with ATX-101 Using Investigator, Subject and Magnetic Resonance Imaging Assessments   When: Long-Term Follow-up Study Oral Presentation Friday, November 4, 2011 4:35 PM EDT…

Kythera Biopharmaceuticals Announces $37.4M Financing
September 19, 2011

Series D Financing To Provide Funding for US Phase III Trials LOS ANGELES, Sept. 19 (Business Wire) – KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”), a privately-held biotechnology company focused on the development and commercialization of products in aesthetic medicine, today announced the closing of a $37.4M Series D financing. The round featured significant new investments as well…

Kythera Biopharmaceuticals Presents Patient Reported Outcomes from Phase IIB Study with ATX-101 Demonstrating Reduction of Submental Fat
March 17, 2011

Data Provides Additional Evidence of Patient Benefit on a Battery of Patient Reported Outcome Measures LOS ANGELES, March 17, 2011 (Business Wire) – KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today presented additional efficacy data from a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental (‘under…

Kythera Biopharmaceuticals Presents Positive Data from Phase IIB Study with ATX-101 Demonstrating Reduction of Submental Fat
February 22, 2011

Results demonstrate statistically significant reduction in submental fat on objective measurement, clinician and patient ratings LOS ANGELES, Feb. 22 (Business Wire) – KYTHERA Biopharmaceuticals, Inc. (KYTHERA) presented results from a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental (‘under the chin’) fat. The…

Kythera Biopharmaceuticals Announces Positive Results from Phase IIB Study with ATX-101 Demonstrating Reduction of Submental Fat
February 4, 2011

First-of-its kind Study using Objective Measurement, Clinician and Patient Ratings LOS ANGELES, Feb. 4 (Business Wire) – KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”) today announced that it has successfully completed a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental (‘under-the-chin’) fat. The Phase IIb, randomized,…

Kythera and Intendis Announce Initiation of European Phase III Clinical Development Program to Evaluate ATX-101 for Reduction of Submental Fat
January 10, 2011

LOS ANGELES, January 10, 2011 – KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”) and Intendis, Bayer HealthCare’s dermatology business, today announced the initiation of two European Phase III studies evaluating ATX-101, a first-in-class injectable adipolytic agent, for the reduction of localized fat under the chin (submental fat). The two multi-center, randomized, double-blind, placebo-controlled, Phase III studies will enroll…

Kythera Biopharmaceuticals to Present at The 29th Annual J.P. Morgan Healthcare Conference
January 6, 2011

LOS ANGELES, January 6, 2011 – KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”), is scheduled to present at the J.P. Morgan 29th Annual Healthcare Conference at 2:00 p.m. Pacific Time on Tuesday, January 11, 2011 at the Westin St. Francis in San Francisco, California. Keith Leonard, KYTHERA’s President and CEO, will be presenting on behalf of KYTHERA and…